Should You Grab This ‘Strong Buy’ Growth Stock With 56% Upside?

Core Insights - BridgeBio Pharma (BBIO) has seen significant investor interest following the approval of its therapy Acoramidis (Attruby) for transthyretin amyloid cardiomyopathy (ATTR-CM) [1] - The company is preparing to launch potentially three new products in 2026, pending approval [1] Financial Performance - BBIO stock has increased over 150% year to date, significantly outperforming the S&P 500 Index, which gained 15% [2] - The stock has been rated a "Strong Buy" by Wall Street analysts, indicating further upside potential [2] Commercial Success - Attruby has generated $110.6 million in revenue for Q2, a substantial increase from $2.2 million in the same quarter last year [3] - U.S. net sales of Attruby accounted for $71.5 million, with strong demand evidenced by 3,751 prescriptions written and over 1,000 prescribers adopting the drug [3] Patient Benefits - Recent analysis of the ATTRibute-CM study suggests that Attruby could become the leading treatment for ATTR-CM, highlighting significant patient benefits [4] Future Prospects - In the next six to twelve months, BridgeBio plans to release findings from three major late-stage programs that could open new markets [5] - For certain genetic ATTR-CM patients, the therapy may reduce mortality or serious cardiac issues by 59%, and patients who rapidly increase their TTR levels show significantly higher survival rates [5]